Vital Therapies Provides Strategic Update

Vital Therapies (Nasdaq:VTL), a biotherapeutic company that has been developing ELAD, a cell-based therapy targeting the treatment of liver failure,...

Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival

Vital Therapies (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure,...